Reata Pharmaceuticals is stopping clinical trials evaluating bardoxolone methyl in people with pulmonary arterial hypertension (PAH), including a Phase 3 study, to ensure the safety of participants during the COVID-19 pandemic, the company announced. Trials in other disorders are set to continue, although some will stop…
The Living Rare, Living Stronger Patient and Family Forum, originally set for May 14–16 in Cleveland, Ohio, has been postponed until July 18–20 because of the coronavirus disease COVID-19 pandemic. The event’s sponsor, the National Organization for Rare Disorders (NORD), said it will still take place at the…
A 62-year-old with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) was successfully treated with immunosuppressants and vasodilators, a case study reports. The unusual antibody linked to her disease, called the anticentriole antibody, may also serve as a marker for the use of immunosuppressives in SSc-PAH patients with this antibody. The…
At 3 a.m. on July 6, 2003, Miami resident Jeffrey Goldstein got a call that would change his life. Doctors at the Duke University Lung Transplant Clinic had found a lung donor match for Goldstein, who had been diagnosed with pulmonary fibrosis two years earlier. Nearly 17 years…
After demonstrating an ability to deliver top-shelf care to patients with pulmonary hypertension (PH), four sites have been added to the Pulmonary Hypertension Association’s (PHA) network of Centers of Comprehensive Care (CCC). The newly accredited centers are the Cleveland Clinic in Ohio, Tufts…
Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based nonprofit she chairs will see the approval of 1,000 new rare disease therapies by 2027. That group, the International Rare Diseases Research Consortium (IRDiRC) —…
The first person with coronavirus disease 2019 (COVID-19) complicating pulmonary hypertension (PH) has received at-home treatment with inhaled nitric oxide (iNO), delivered through the Genosyl system, according to VERO Biotech, manufacturer of Genosyl. The PH patient with COVID-19 infection was treated under the terms of an emergency…
People with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — particularly those showing low or intermediate disease risk, typical PAH — benefit most from combination therapy with Letairis (ambrisentan) and Adcirca (tadalafil) than from either therapy alone, according to an exploratory sub-analysis of a Phase 3…
Treatment with Orenitram (oral treprostinil) is associated with lower healthcare-related costs than treatment with Uptravi (selexipag) in people with pulmonary arterial hypertension (PAH), a new study suggests. The study, “Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective…
Among people with chronic thromboembolic pulmonary hypertension (CTEPH), certain anticoagulants may reduce the risk of serious bleeding more than others, a new study shows. The study, “Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational…
The Phase 2 HELP study testing levosimendan as a potential treatment for pulmonary hypertension (PH) has exceeded its target number and is fully enrolled, Tenax Therapeutics announced. The trial (NCT03541603), testing the potential therapy in PH patients with heart failure…
Bellerophon Therapeutics has reached an agreement with the U.S. Food and Drug Administration (FDA) setting the design of an upcoming, pivotal Phase 3 clinical trial testing INOpulse, an investigational therapy, in people with pulmonary fibrosis (PF) who are at risk of pulmonary hypertension (PH). PH-PF is characterized…
Get regular updates to your inbox.